Experts discuss the current role of checkpoint inhibition in hepatocellular cancer (HCC) as well as the emergence of combination therapies.
The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of HCC.
This activity is intended for hematologists/oncologists, gastroenterologists, nurses/nurse practitioners, pharmacists, and other healthcare professionals who treat patients with advanced hepatocellular cancer.
- Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) in managing unresectable HCC.
- Have greater competence related to identifying when an ICI should be considered for a patient with unresectable/advanced HCC.
- Have greater competence related to managing immune-related adverse events (irAEs) in patients with unresectable HCC.
Approximate Time to Complete: 45 minutes
Credit Available: May 8, 2020 - May 8, 2021
Developed through a partnership between SITC and Medscape.
Additional Resources for Clinicans from SITC: